Favipiravir vs Standard care/Placebo (RCT)

Mild outpatients

Study Dabbous HM, Scientific Reports, 2021 has been retracted on September 18, 2021. The study was excluded from the analysis and grade assessment by October 10 the latest.

FOREST PLOTS -2022-05-16

Studies description

Trial NCT04464408
Publication Bosaeed M, Clin Microbiol Infect (2022) (published paper)
Dates: 2020-07-23 to 2021-08-04
Funding: Public/non profit (King Abdullah International Medical Research Center (KAIMRC).)
Conflict of interest: No

Trial NCT04346628
Publication Holubar M, Clin Infect Dis (2022) (published paper)
Dates: 2020-07-08 to 2021-03-23
Funding: Public/non profit (Anonymous donors to Stanford University)
Conflict of interest: No

Trial NCT04499677
Publication FLARE - Lowe DM, medRxiv (2022) (preprint)
Dates: 2020-10-06 to 2021-11-04
Funding: Mixed (LifeArc, UK; Fujifilm Toyama Chemical Co. provided favipiravir and favipiravir placebo free of charge.)
Conflict of interest: Yes

Trial NCT04333589
Publication Zhao H, Int Immunopharmacol (2021) (published paper)
Dates: 2020-03-27 to 2020-05-09
Funding: Public/non profit (Chinese COVID-19 scientific research emergency; China Mega-Project for Infectious Diseases; China Mega-Project for Innovative Drugs)
Conflict of interest: No